Why BioXcel Therapeutics Stock Triumphed This Week

Why BioXcel Therapeutics Stock Triumphed This Week

Investors were good to BioXcel Therapeutics (NASDAQ: BTAI) stock this week, particularly after a top-shelf investment bank upgraded its recommendation on the shares. All told, in the Monday to Friday trading period, the company's stock price rose by more than 16%, according to data compiled by S&P Global Market Intelligence. The upgrader was Goldman Sachs' (NYSE: GS) Corinne Jenkins, who now feels the stock is neutral.